arGEN-X is an innovative biopharmaceutical company transforming the development of human therapeutic antibodies. Its vision is to create novel, antibody-based medicines with the potential to have a meaningful impact on patients' lives.
arGEN-X breakthrough SIMPLE Antibody™ discovery platform generates an unparalleled diversity of antibody leads against any disease target. Unrivalled lead choice in discovery ensures selection of only the highest quality antibodies for development, thereby maximizing the probability of their success as products.
SIMPLE Antibodies routinely exhibit gold-standard functional potencies and outstanding manufacturability without the need for additional engineering.
arGEN-X strategy is to apply its cutting-edge technology and in-depth know-how to high-value disease targets to create innovative therapeutic antibody candidates for its own portfolio and as part of strategic partnerships.
arGEN-X is made up of a close-knit team of antibody specialists, combining over 50 years of complementary expertise and with a successful track record in research, development and business development.
